Three physicians and two patient advocates discuss their concerns with the non-medical switching of biologic medicines by third parties such as insurers or pharmacy-benefit managers (PBMs).

ASBM’s Chair, Madelaine Feldman, MD FACR is joined by ASBM’s Immediate Past Chair, Harry Gewanter, MD MACR; and ASBM’s Founding Chair, Richard Dolinar, MD; to discuss physician perspectives on NMS. The patient perspective is provided by two ASBM Steering Committee Members: Andrew Spiegel of the Global Colon Cancer Association (GCCA); and Kathleen Arntsen of Lupus and Allied Diseases Association (LADA).